Interstitial lung disease in systemic sclerosis
Authors:
- Luc MouthonLMLuc Mouthon
- 1 March 2011
- journal article
- review article
- Published by Elsevier in Autoimmunity Reviews
- Vol. 10 (5) , 248-255
Abstract
No abstract availableKeywords
This publication has 87 references indexed in Scilit:
- Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle studyRheumatology, 2009
- The treatment with N-acetylcysteine of Raynaud’s phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patientsClinical Rheumatology, 2009
- A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamideRheumatology, 2008
- Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Changes in causes of death in systemic sclerosis, 1972–2002Annals of the Rheumatic Diseases, 2007
- A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosisClinical Rheumatology, 2006
- IgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patientsClinical Immunology, 2004
- The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosisClinical Rheumatology, 2003
- Predicting Mortality in Systemic SclerosisMedicine, 2002
- Interferons and Collagen ProductionJournal of Investigative Dermatology, 1990